Visualizing RNAi at Work
News Jul 06, 2015
The phenomenon of RNAi is expected to find applications in medical treatments. RNAi is mediated by RNA-induced silencing complex (RISC), which contains a small RNA and an Argonaute protein at its core and cleaves the target RNA. However, there were no suitable tools to directly monitor the RNAi reaction and its molecular mechanism by which RISC cleaves the target RNA has remained unclear.
Now, a research group at the University of Tokyo (Professor Takuya Ueda, Professor Yukihide Tomari, Researcher Chunyan Yao and Research Associate Hiroshi M Sasaki,) and at Kyoto University (Researcher Hisashi Tadakuma), has developed a single-molecule imaging assay for observing target RNA cleavage by RISC in a test tube in real time for the first time, showing how RISC accurately cleaves and releases targets. Specifically, their obsercations provide direct evidence for the model that the small RNA in the RISC consists of two parts, one of which quickly binds to the target RNA to be cleaved, while the other proofreads that the correct RNA has been found.
This groundbreaking result reveals RISC’s molecular mechanism of action and the illustration of this process was adopted as the cover design of this issue of the journal. This achievement will also contribute to accelerating the research applications of RNAi such as to the development of RNA-based next-generation drugs, for example as gene therapy to suppress the production of a disease-causing protein.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Who Owns the Ocean? One Company Has Registered Half of All Marine Gene PatentsNews
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.